Background: There is significant interest in comparing countries on many different indicators of social problems and policies. Cross-national comparisons of drug prevalence and policies are often hampered by differences in the approach used to reach respondents and the methods used to obtain information in national surveys. The paper explores how much these differences could affect cross-country comparisons. Methods:
Introduction
No discussion of social problems or social policy is complete today without comparisons with other countries. How well educated are British 15 year olds; look up their scores in the Program for International Student Assessment (OECD, 2016) . How awful is homicide in America; look at UNODC's report on World Homicide Rates (2014). It is hardly surprising that there is growing interest in making comparisons for drug problems as well.
Unfortunately, there are few internationally standardized measures of drug prevalence available; two European-wide school surveys (the European School Survey Project in Alcohol and Drugs and the WHO Health Behavior in School-Aged Children) and, very occasionally, a general population survey (GPS) in a broader array of countries.
Thus, several international comparisons of substance use and its consequencesincluding the World Health Organization estimates of the burden of disease (Degenhardt and Hall, 2012 )-partially rely on figures from national general population surveys.
These general population surveys are now fairly standardized in terms of the key drug use questions, such as recentness of consumption (lifetime, last year, or last month) or type of drug used (e.g. cannabis, heroin, etc.). This gives an illusion of comparability or downplays methodological issues affecting cross-country comparability such as differences in the mode of questioning (Gowing et al., 2015; Mounteney et al., 2016) .
Prevalence surveys employ two main approaches to administer the questionnaire, Self-Administered Questionnaires (SAQ) and Interviewer-Administered Questionnaires (IAQ) and different modes of gathering information; e.g. Pencil & Paper (P&P), telephone-assisted and computer-assisted. Multiple studies have shown that the type of interaction between interviewer and respondent affects the estimated prevalence rates for sensitive behaviors. For example, SAQ will produce higher rates than IAQ (Aquilino, 1994; Bowman-Bowen and Menard, 2016; Turner et al., 1992) . The specific method of implementation of a modality also has consequences. For example, Audio Computer Assisted Self Interviews (ACASI) produce higher rates than traditional Pencil and Paper (P&P) methods for SAQ interviews (Lessler et al., 2000; Lessler and O'Reilly, 1997; Turner et al., 1998) . This paper explores how much these differences affect the comparisons that are reported in various studies (Gowing et al., 2015; Greenwald, 2009; MacCoun, 2011; Mounteney et al., 2016) . The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the source for most of our data, reflecting the fact that it has pioneered efforts to make such cross-national comparisons on a regular basis. The paper reports the results of a preliminary effort to normalize reported prevalence in general population surveys and explore how much that affects the rankings of countries.
Background
Mode of questioning affects the reporting of any behavior, but in particular, sensitive behaviors, such as drug use. Differences arise from variations in respondent willingness to report sensitive information in a particular mode (Aquilino, 1994 (Aquilino, , 1997 Beck et al., 2002; Corkrey and Parkinson, 2002; Cox et al., 1992; Turner et al., 1992) , the likelihood of reaching the respondent, and by catching response inconsistencies during the interview (Lessler et al., 2000; Wright et al., 1998) .
Modes of questioning that offer a greater prospect of confidentiality are associated with increased respondent willingness to report drug use. Every survey implements some protocols aiming at affording a higher perception of privacy to the respondents. For instance, sensitive information and personal details that could identify the respondent are often kept in separate files (Aquilino, 1997) . However, respondents are rarely aware of these protocols and much of their willingness to disclose drug use depends on the anonymity granted by the method of collection. For these reasons, most of the surveys aiming at measuring sensitive behaviors (drug use, sexual practices, etc.) do not use an IAQ but a SAQ. Several studies show that SAQs report a higher estimate of drug use than IAQ interviews (Aquilino, 1994 (Aquilino, , 1997 Cox et al., 1992) . SAQs allow researchers to give a higher degree of privacy to the respondent in the possibility to complete the questionnaire in private and then return it in a sealed envelope. The same logic works for telephone interviews. Telephone surveys can be conducted through a Computer Assisted Telephone Interviewing (CATI) or an audio computer-assisted self-interviewing (T-ACASI). In the CATI the computer dials the telephone number to be called and the interviewer reads the questions and records the respondent's answers into the computer.
In the T-ACASI the computer reads the question to the respondent who answers by pressing numbers on the touch-tone telephone; this results in higher prevalence rates (Corkrey and Parkinson, 2002; Turner et al., 2005) . Reporting drug use to a telephone interviewer raises the same concern that respondents have in face-to-face surveys. P&P, SAQs, and T-ACASI guarantee a higher level of privacy and anonymity.
Modern computerized SAQs -i.e. Computer Assisted Self-Interview (CASI) and ACASI -reduce the errors and response inconsistencies inherent in traditional P&P (Lessler et al., 2000; Lessler and O'Reilly, 1997; Tourangeau and Smith, 1996; Tourangeau and Yan, 2007; Wright et al., 1998) . Computer SAQs may be programmed to detect and edit inconsistencies or to employ 'skip patterns' which avoid giving respondents questions that do not logically apply to them given their previous answers.
For instance, if respondents report their last drug use more than 30 days ago they cannot report any drug use in the previous month (Cox et al., 1992) . ACASI also allows those with limited reading ability to easily answer the questionnaire. Indeed the ACASI system administers questions that have been digitally recorded to which respondents may listen using headphones. Finally there is some evidence that computer SAQs may increase respondents' perception of privacy and anonymity (Lessler et al., 2000; Tourangeau and Smith, 1996) . Some factors -in particular age, sensitivity of the item, and recentness of the consumption being reported -modulate the effect of the mode of questioning in reporting drug use. The impact of the mode of questioning varies substantially across age, with teenagers more inclined to report drug use to surveys using instruments guaranteeing a higher level of privacy and anonymity (such as CASI rather than P&P). For instance, Wright et al. show the difference in reporting sensitive behaviors between a classical P&P and SAQ and CASI among respondents aged 12-18 and 19-34 (Wright et al., 1998) . The 19-34 group does not show significant differences in reporting alcohol use in the previous year (both CASI and P&P -SAQ groups report a prevalence of about 42%). In contrast, those using P&P -SAQ in the 12-18 group report a prevalence of 18.5%, while those interviewed with CASI report a last year prevalence of alcohol use of 28.4%. Beside these, other factors may modulate the effect of mode of interview in reporting consumption of illicit drugs. These factors are in the background -such as home v school; the presence of another at the moment of the interview (parents or spouse); race or ethnicity; and level of mistrust (Aquilino, 1997; Beck et al., 2002; Schober et al., 1992; Wright et al., 1998) .
The effect of survey methods in disclosing sensitive behaviors decreases as the response moves from recent to less recent drug use. Indeed respondents are less willing to report drug consumption in the last month than lifetime consumption. Table 1 shows cocaine consumption prevalence in the last month (LMP), last year (LYP), and in life (LTP) according to the results presented by Turner et al., (Turner et al., 2005) . Reporting cocaine prevalence in the last month increases threefold moving from CATI to T-ACASI while lifetime prevalence increases of just 1.2 times. Similarly, survey methods granting a higher level of privacy and anonymity are generally more effective in disclosing stigmatized than socially acceptable behaviors. Table 2 reports prevalence of drug use in the last month for alcohol, marijuana, and cocaine using SAQ -P&P and IAQ -P&P (Turner et al., 1992) . For the all three substances the SAQ shows higher use, with the SAQ:IAQ ratio increasing as we move from the least stigmatized (alcohol) to the most stigmatized substance (cocaine). Two criteria guide the inclusion of countries in the standardization. The first is the availability of data from national household surveys. As such, we included in the analysis European countries -for which the EMCDDA provides detailed information about levels of prevalence and metadata -the United States (SAMHSA, 2014), Australia (AIHW, 2014), and Canada (Health Canada, 2015) . The second criterion is the availability of a conversion factor between surveys using a different mode of questioning.
We considered just those countries employing survey methods for which we have been able to calculate a conversion factor for standardizing prevalence across countries. For instance, the figures below do not report data for Germany because in the last household survey it employed a multi-method survey (mail, phone, internet) for which the literature does not provide data for standardizing with other surveys.
To identify the relevant literature, we reviewed the most-cited scientific journals for the categories substance abuse and searched the databases offered by Medline and Google Scholar. Table B in the appendix summarizes the results of this search. Then we considered age, recentness, and type of substance in the elaboration. We calculated conversion factors from studies reporting differences in consumption for the adult population and not for adolescents only. Similarly, we compared the same kind of prevalence (LMP and LYP) and substance (cannabis and cocaine). These factors modulate the effect of the survey method in reporting drug use and omitting them could heavily bias the results. Where more than one study provided a conversion factor, we calculated the average. Table 3 shows the conversion factors used to adjust and standardize levels of prevalence across countries (see Tables C, D and E in the appendix for additional information). This study does not aim to estimate 'true consumption' nor to develop conversion ratios to make reported level of drug consumption comparable across countries. Respondents to drug consumption questions are likely to underreport their consumption (Colón et al., 2002; Harrison et al., 2007) . It is common to correct this underreporting by adjusting estimates upward (Kilmer et al., 2011) ; however, willingness to report sensitive questions such as use of illicit drugs may vary across countries and time. All the adjustment factors calculated in this study are based on US data and might not apply to other countries. People can be more reluctant to report drug use in countries with a stricter enforcement of drug use than where the enforcement of illicit drugs is less intense. The same can be true if a country changes across years its policy and cultural attitude towards drugs (Chalmers et al., 2016 Wright et al., 1998; Tourangeau and Smith, 1996; c Lessler et al., 2000; d Aquilino, 1994 ; e Schober et al., 1992;  f Turner et al., 1992 Table 3 . Although the correlation among unadjusted and adjusted prevalence rates is high (r = .877 and Spearman's rank correlation (r s) = .928), there are some important differences. After the standardization, the US moves from first to third ranked for last month cannabis prevalence. In Figure 1 Figure 3B shows that, after adjusting for the conversion factor, Ireland (2.1%) reports almost the same prevalence as the neighboring UK (2.4%). Similarly, the US shows a level of consumption lower than the Netherlands. 
Results

Discussion
It is not uncommon to find popular media sources announcing "Country X top world consumer of drug Y" (Lee, 2014; Smith, 2015; Travis, 2016) . These league tables of drug prevalence are not restricted to the media but also sometimes appear in scientific papers (Mounteney et al., 2016; Zobel and Götz, 2011) . This analysis shows that country rankings are partly an artifact of the mode of interview. The methods of contacting respondents and the technology for questioning respondents in household surveys complicate cross-country comparisons. For instance, Figure 1 A, Figure 2 A, and Figure   3 A show that using unadjusted general population surveys, the United States has the highest prevalence rates for several indicators of drug prevalence. The analysis shows that this result may partially reflect that the US employs a modality (ACASI) that is known to produce higher estimates for a given population. Differences can seem modest but our comparison is limited to a small subset of countries driven by the availability of data.
Bigger differences can emerge if this exercise is extended to several countries.
Research also suggests that survey differences can in particular affect the cross-country comparison of the most useful drug prevalence measures for policy analysis. Survey mode has little impact on life-time prevalence, a measurement that is of little use for policy purpose since it might refer to people who consumed drug many years ago. Pastmonth prevalence, a measure often used to estimate the number of regular drug users, is much more influenced by instruments guaranteeing a higher level of privacy and anonymity in the survey. The effect of survey modality can then be negligible when comparing generational dynamics of drug taking but can considerably affect the comparison of current (LYP) and regular (LMP) drug use across countries. Similarly, the influence of survey differences can be limited for more socially acceptable drugs (e.g. cannabis) than for highly stigmatized substances (e.g. cocaine). The good news is that it is possible to improve comparability. Our analysis was just a demonstration of the effect that survey differences can have on cross-country comparisons of drug use prevalence.
We cannot conclude that our adjustment made drug use measures more comparable as the conversion factors rely primarily on data from US surveys. We suggest, instead, that more studies on the impact of survey modality should be carried out across different The coverage of the population also varies across countries. Age range is an important factor defining target population. Most European countries follow the EMCDDA recommendation and restrict coverage to the group age 15-64 (see Table a in the appendix). Australia (14+), Canada (15+), Denmark (16+), and the United States (12+) do not provide an upper age limit while the lower limit varies between 12 (Greece and the United States), and 18 (Germany). Countries can easily adjust prevalence estimates to the group 15-64 when collecting data for broader ranges. For some countries, (e.g. Germany, UK, etc.), however, the targeted age group is narrower. For these countries the EMCDDA does not make any adjustment (personal communication with Jane Mounteney).
Differences across countries in the number of institutionalized people may also affect cross-country comparability. While all surveys exclude the imprisoned population, that is a much more important exclusion for the United States than for any Western European country, since the incarceration rate in the US (ca. 700 per 100,000) is about seven times that for most EU member states (Walmsley, 2016 The issue of cross-country comparability is not limited solely to drug use prevalence but affects also other drug-related indicators, such as mortality, the burden of disease, and treatment penetration (Kilmer et al., 2015) . Cross-country comparisons are possible but need care in interpretation. International surveys should be privileged over national household surveys for identifying main patterns. Comparisons of national surveys should explicitly take account of modality and adjust for targeting the same age group, and when possible be cross-checked with other sources.
Ignoring these differences and how they can influence cross-country comparisons may lead to incorrect inferences and misinterpretation of the effect of drug policies. The good news is that so far the effects have been modest. 
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